AllAnalyst Report
Morningstar•August 11, 2022
Morningstar•August 11, 2022Sanofi: GSK and Sanofi Stock Price Changes With Growing Zantac Litigation; Concerns Look Like Overreaction
Summary
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regen
Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Actions
Download Full ReportRelated Reports
- Analyst Report: Johnson & JohnsonApr 18, 2024 •
JNJ
- Market Update: DFS, JNJ, LVS, TRVApr 18, 2024 •
DFS, JNJ, LVS, TRV
- Analyst Report: Abbott LaboratoriesApr 17, 2024 •
ABT
- Analyst Report: Eli Lilly and CompanyApr 17, 2024 •
LLY
- Analyst Report: Johnson & JohnsonApr 16, 2024 •
JNJ
Analyst Profile
Damien Conover
Sector DirectorDamien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.